Shankar Siva

Shankar Siva: SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma

Shankar Siva, Radiation Oncologist at the Peter MacCallum Cancer Centre, shared a post on X about recent paper by Constanza Vargas et al.:

“New trial analysis from FASTRACKII: in kidney cancer, SABR increased efficacy and decreased cost than radiofrequency or cryoablation.

  • QALYs: SABR 4.00 vs RFA/CA 3.07
  • Cost: SABR A$31,053 vs RFA A$35,001 vs CA A$36,356
  • Net savings ~$4K/patient.”

Title: SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II Trial

Authors: Constanza Vargas, Joe Carrello, Mathias Bressel, Mark Sidhom, Charles Lin, Ben Vanneste, Daniel Moon, Sree Appu, Anand Swaminath, Jeremy Ruben, David Pryor, Braden Higgs, Ryan Davey, Nicholas Hardcastle, Rebecca Montgomery, Shankar Siva, and Richard De Abreu Lourenço

Read The Full Article at International Journal of Radiation Oncology*Biology*Physics.

Shankar Siva: SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma

More posts featuring Shankar Siva on OncoDaily. 

Anand Swaminath and Richard De Abreu Lourenço Ben Vanneste Braden Higgs cancer Charles Lin Constanza Vargas Daniel Moon David Pryor FASTRACKII Jeremy Ruben Joe Carrello Mark Sidhom Mathias Bressel Nicholas Hardcastle OncoDaily Oncology Rebecca Montgomery Ryan Davey Shankar Siva Sree Appu